antidepressants in oncology
DESCRIPTION
MedicinaTRANSCRIPT
1
Antidepressants in Oncology: Reason and Choice
Riccardo GV Torta, MD; Marco Miniotti, PsycholD, and Paolo Leombruni, MD
Corresponding author: Prof. Riccardo GV Torta
Department of Neuroscience, University of Turin
Clinical and Oncological Psychology Unit,
Via Cherasco 15, 10126, Turin, Italy
Telephone: 0039-011-6636327
Fax: 0039-011-6963487
Email: [email protected]
Acknowledgments
None.
Funding
No funding was received for this article.
Declaration of interest
The authors report no declarations of interest.
Other disclosures
None.
2
Summary
The medications known as antidepressants are the group of psychotropic drugs used most often in
psycho-oncology for their wide spectrum of action, ranging from mood improvement to the control
of anxiety and pain. Antidepressants are drugs that act on the whole body rather than just the central
nervous system. They also modulate the hormonal and immune systems, particularly normalizing
stress-induced alterations. In oncology, the choice of an antidepressant must involve consideration
of the symptoms and the dimensional aspects more than strict diagnostic criteria. A careful
evaluation of the balance between effectiveness and safety, considering the possibility of
interactions between antidepressants and oncological treatments, is crucial. In that context, this
paper discusses each class of antidepressant relative to the present research literature concerning the
specific use of each drug in oncological patients, noting that criteria of effectiveness and safety can
differ from those established for the general psychiatric population without organic comorbidity.
Finally, some aspects of the use of antidepressants in the treatment of patients with pain will be
discussed, as these drugs exert an intrinsic antalgic activity even when depressed mood is not
present. Indeed, antidepressants act not only on the somatic modulation of pain, but they are also
effective on the emotional and cognitive aspects of pain, therefore intensifying the analgesic activity
of traditional painkillers.
Key words
Antidepressants, Oncology, Pain.
3
Introduction
Despite evidence that the treatment of depression induces a significant improvement of the patient’s
quality of life and reduces mortality from cancer, pharmacological treatment is used in less than 5%
of depressed oncological patients (1-4). Furthermore, the use of antidepressants is no longer limited
to the treatment of mood disorders but has been expanded to include treatment of anxiety disorders,
pain and the somatic consequences of chronic stress (5).
Within psycho-oncology, it is important to reduce the use of several classes of drugs, such as
benzodiazepines and neuroleptics, that mainly exert a symptomatic and tactical activity that is
useful in critical situations and short term interventions, but their use is inadvisable as long term
treatments because of their propensity to increase fatigue. More appropriate is the use of
antidepressants (and sometime atypical antipsychotics) that exert a curative activity and, for newer-
generation antidepressants, have a high safety in long-term treatments (6).
In fact, the first criteria that must be met when choosing a psychopharmacological compound in
psycho-oncology relate to safety and tolerability, noting that these criteria can change among the
different oncotypes. An antidepressant must primarily manage specific clusters of symptoms that
are more frequent in depressed oncological patients, including pain, fatigue, hyporexia and weight
loss; these symptoms are no less important than nuclear depressive symptoms such as anhedonia
and mood deflection.
The next step in choosing a compound will be the evaluation of pharmaco-dynamic and kinetic
characteristics of antidepressants, particularly when used concomitantly with oncological drugs. For
example, the use of paroxetine with taxanes is to be avoided, and caution must be used to prevent
specific side effects that can be devastating in some patients, such as the anticholinergic activity of
tricyclic antidepressants (TCA) in patients with reduced gastrointestinal motility, the additive effect
4
of serotonergic antidepressant-related nausea with similar chemotherapeutic side effects, or an
antihistaminergic sedation in asthenic patients (7-9)
Iatrogenic factors inducing depression
Several drugs used in general medicine and sometimes in oncological patients, such as beta-
blockers, anti-hypertensive drugs, and barbiturates, can induce depression. In addition, the
widespread use (for nausea or sedation) of high-potency neuroleptics, such as haloperidol, can
cause dopaminergic depletion with consequent depression. Alternatively, corticosteroids can induce
both depression and elation, depending on the individual’s response.
Special attention must be paid to the use of interferon because of the possibility of its inducing a
worsening of mood, related to the increase of pro-inflammatory cytokines (10-13).
Also of note, an iatrogenic estrogenic depletion (surgically or pharmacologically induced) can cause
a severe depression and an increase of the hot flushes phenomenon. For the latter, an estrogenic
implementation is obviously inconvenient, and several antidepressants have demonstrated good
effectiveness, with a normalization of thermoregulation due to estrogenic production within the
central nervous system induced by antidepressants (14-15).
It is very important to be aware that the neurotoxicity caused by several chemotherapeutic agents
(e.g., taxans, vinca alkaloids, or heavy metals) can induce not only peripheral neuropathies but also
cognitive and emotional problems, such as depressed mood, memory impairment, and irritability
(16-20).
Reasons for an antidepressant intervention in oncological patients
Depression in oncological patients causes a worsening of quality of life, a higher risk for the
emotional and somatic consequences of chronic stress, physical, social and occupational functional
impairment, a reduced adherence to diagnostic procedures and treatments as well as a dramatic
5
increase in suicide risk. In spite of the high prevalence of depression in oncological patients (with
wide variability depending on the disease phase and treatment), only a small percentage of
depressed oncological patients take advantage of antidepressant treatment (4, 21-24). The poor
management of depression increases pain perception and reduces the patient’s tolerance for the side
effects of oncological therapies.
It is mandatory to make a correct diagnosis of any form of depressed mood in a patient with cancer.
Recommendations include using self-evaluation instruments and then studying in depth, with a
semistructured clinical interview, those patients that demonstrate scores higher than a screening cut-
off (25).
A serious clinical mistake is to consider depression in oncological patients as an unavoidable
pathology and consequently not responsive to drugs. The correct antidepressant treatment can
improve depression in oncological patients similarly to functional depressed patients (26).
However, an antidepressant’s effectiveness in oncology must be evaluated not based on a simple
rating scale score reduction but, above all, based on functional recovery, improvement in the quality
of life and the change toward more adaptive coping styles.
The pathogenesis of emotional disorders in oncology is strictly related to the biopsychosocial
model, with differing importance among individuals and disease phases of the biological,
emotional-cognitive and social components. Consequently, the most efficacious therapeutic
interventions will be an integration of a pharmacological intervention to correct the biologic
alterations (e.g., transmitter-related, hormonal, immunological, and neurotrophic) and/or a tailored
psychotherapy to modify the patient’s cognitive and emotional defense strategies and/or supporting
the patient when the social context problematically affects emotional parameters.
In this context, antidepressants are the most efficacious class of medication because of their activity
on mood, anxiety, stress, and pain (27,28).
6
Guideline for the use of antidepressants in oncological patients
When the diagnosis of depression is made, antidepressants must be used as the pharmacological
first line of treatment. In fact, the use of benzodiazepines when depressive symptoms are present is
still frequent. Oncologists should have a basic knowledge of antidepressants to prescribe as a first
step for patients that refuse a psychiatric consultation, thus avoiding the consequences of lack of
treatment and maintaining direct management of the patient. The most favorable conditions are the
presence of a medical psycho-oncologist on the oncological team or the presence of a dedicated
psychiatrist, expert in the use of antidepressants in oncological patients.
In oncology, the greatest risk of non-adherence is present in the first weeks of an antidepressant
treatment, when side effects outweigh the therapeutic response. This is because the latency of
antidepressant activity on anxiety and mood is about three to four weeks. During this latency
period, it is essential to provide the patient with adequate information, psychosocial support (from
the therapeutic staff and family) and, when necessary, pharmacological management of the
antidepressant’s side effects (such as activation, nausea, or dizziness).
In almost all patients with severe depression, suicidal ideation can be present. An increased risk of
suicide is likely in those patients in which a psychomotor disinhibition, induced by an
antidepressant, takes place before a nuclear improvement of depression is reached. In this situation,
for an outpatient, monitoring of the patient by the family is mandatory, and it is important to have
an open and reassuring discussion with the patient concerning his or her suicidal ideation. In all
patients with chronic severe uncontrolled pain and depression, the suicide risk is significantly
increased (29).
Antidepressants behind depression
Depression as a consequence of a reduction of neurotransmitters is the major hypothesis used to
explain several clusters of symptoms that can be specifically linked to a serotonergic, dopaminergic
7
or noradrenergic deficits. Likewise, the current classification of antidepressants is based on this
neurotransmitter-related hypothesis: selective serotonergic reuptake inhibitors (SSRIs), selective
noradrenergic reuptake inhibitors (NARIs), and serotonergic and noradrenergic reuptake inhibitors
(SNRIs).
If depression is actually a systemic disease, seen not only the neuropsychiatric context but also as a
disease that involves the total body, other pathogenetic hypotheses complementary to the
neurotransmitter-related hypothesis must be considered.
Moreover, the neurotransmitter-related hypothesis of depression must be considered as a systemic
pathology because 5HT, NE and DA are systemic transmitters and not only transmitters within the
brain. In contrast, depression can also be related to hormonal, immunological, and trophic
alterations. In the hormonal hypothesis of depression, several circuits are involved: the
hypothalamus-pituitary-adrenocortical axis (HPA), the hypothalamus-pituitary-gonadic axis (HPG)
and the hypothalamus-pituitary-thyroid axis (HPA).
An important relationship exists between estrogen levels and mood, as confirmed by depression
during menopause or after delivery; as previously mentioned with respect to the problem of hot
flushes, antidepressants are able to increase the estrogen level produced within brain, thereby
regulating the emotional responses related to these hormones.
Concerning the HPA axis, it is well known that stress circuits are involved in the modulation of
anxiety and mood symptoms (30). The first step in the activation of the HPA axis, that is, the
release of the hypothalamic factor CRF (Cortisol Releasing Factor), is in itself able to immediately
activate the same behavior and autonomic responses that are reinforced by the activation of HPA
circuits in toto, that is, ACTH, cortisol, vasopressine and so on. Within these circuits,
antidepressants reduce the excessive CRF response and the downstream cortisolemic and autonomic
alterations.
8
The chronic release of glucocorticoids during a prolonged HPA activation can induce hippocampal
neuronal death and, consequently, a shrinkage of this area, as found in several neuroimaging studies
of pathologies characterized by chronic stress (i.e., depression, schizophrenia, bipolar disorder, and
post-traumatic stress disorder) (31).
With regard to the neurotrophic hypothesis of depression, antidepressants exert a protective activity
on hippocampal neurons through an increase of the antidepressant-induced production of
neurotrophic factors, such as BDNF and NGF (32-34). In oncology, such neurogenic effects
facilitated by antidepressants can be useful to counteract the neuronal damage induced by some
chemotherapies, thus reducing the neuropathic, cognitive, emotional and biological consequences
during chemotherapies (36, 37).
Of major importance for the use of antidepressants in oncology is the immunological hypothesis of
depression, that is, that chronic stress can induce a “neuroinflammation” through an increased
release of pro-inflammatory cytokines. Particularly at the Central Nervous System (CNS) level, the
activation of microglia causes several responses, including on the one hand, an increase of pro-
inflammatory cytokines, a reduction of glutamate reuptake and an increase of glutamate release
(increasing excitoxicity) and on the other hand, an induction of IDO, an enzyme that can divert
tryptophan from the pathway of serotonin production (causing depression) to the pathway of
kinurenines (more details in 38).
An example of the clinical consequences of cytokine increase is a cluster of symptoms (such as
apathy, hyporexia, increased sleep, libido reduction, and hyperpathy) that are similar during
inflammatory diseases (the so-called sickness behavior) and depression. This cluster may be due to
the same background in both pathologies, that is, it may be linked to cytokine activation.
The role of antidepressants in this pathogenetic key is well demonstrated in that they induce an
increase of anti-inflammatory cytokines that counteracts the depressing activity of pro-
9
inflammatory ones. This statement is largely confirmed by the protective activity exerted by
antidepressants against depression induced by interferon (10, 11).
The choice of an antidepressant in oncology
The choice of an antidepressant in oncology must correlate more strictly with the dimensional
characteristics of depression, such as the particular symptomatological clusters of each patient, than
to rigid categorical criteria as defined by the nosographic manuals (such as DSM or ICD) because
these latter criteria are not suitable in cases of comorbidity.
In the choice of a drug, we have first to consider the following: 1) the clinical-symptomatological
dimensions that are related to different kinds of cancer (for example, gut motility in colon cancer,
the prolactin pharmacological growth in hormone-dependent breast cancer, or the presence of
uncontrolled pain); 2) the phase of the cancer disease (an unwanted side effect, for example,
sedation, can become useful in another situation in the same patient); 3) the risk of additive effects
of antidepressant side effects and concomitant chemotherapeutic side effects (for example,
mucositis from chemotherapy and dry mouth from TCAs, nausea from chemotherapy or nausea
from serotonergic antidepressants); 4) the need to change psychopharmacological intervention
based on changing symptoms (for example, anxiety, insomnia, fatigue, or pain).
Another step in making the choice of an antidepressant is to consider the pharmaco-dynamic and
kinetics characteristics, particularly concerning the possible interaction with oncological drugs
during polypharmacotherapeutic interventions. For example, when a women is taking tamoxifen,
the serotonergic antidepressant paroxetine must be avoided (see section “interactions”), or the risk
of a serotonergic syndrome is increased when tramadol (analgesic) and venlafaxine (antidepressant)
are prescribed together (39,40).
Antidepressants classes in oncology: the pros and cons
10
The wide range of choice among different classes of antidepressants and among antidepressants
within each class allows for treatments tailored to each patient, with particular regard to the balance
between effectiveness and safety of such a therapeutic regimen.
Some antidepressants are not usually used in psycho-oncology for problems of safety, for example,
the Monoamino-Oxidase Inhibitors (MAO-I), and such classes will not be treated in this article.
Tricyclics (TCAs), which are first-generation antidepressants, have a broad spectrum of action (on
5HT and NE) and also a strong activity of blockade on several receptors (i.e., adrenergic,
histaminergic, and muscarinic). With this profile, TCAs demonstrate a high presence of autonomic
side effects (i.e., dry mouth, constipation, and orthostatic hypotension) that are very restricting in
oncological patients; the effectiveness is good (40-50% of oncological patients with depression
respond), but the tolerability is low (17-32% of treated patients drop out) (21).
Moreover, TCAs are cardiotoxic, with a delayed conduction, a QTc prolongation and possible
rhythm alterations, with particularly high risk in oncological patients with a cardiomyopathy
secondary to chemotherapy or radiotherapy (41, 42).
Amitriptyline is useful in neuropathic pain, but in this context, the high incidence of dose-related
side effects requires low dosages (mainly less than 50 mg), which are enough for antalgic activity
but are inadequate for mood treatment and, consequently, are unable to restore the pain threshold
lowered by depression (43).
Trazodone is a non-tricyclic antidepressant used fairly often in psycho-oncology, which
demonstrates at low doses an inhibition of the 5HT reuptake, but at high doses is a 5HT agonist;
this activity due probably to its main metabolite. Trazodone exerts a sedative activity through its
alfa-1 and H1 blockade and is frequently used at a dose approximately 50-75 mg in the evening as
alternative to BDZs when these compounds are inappropriate. The dosage useful for antidepressant
11
activity is approximately 150-300 mg/day (44). Its efficacy on insomnia and delirium suggests the
possible use of trazodone also in palliative care (45).
Reboxetine is a norepinephrine reuptake inhibitor (NARI) that demonstrates an activating and
socializing activity without significant metabolic interactions. The main problem in oncological
patients is the frequent and sometime severe urinary hesitancy in men with present or potential
urinary troubles. The use of reboxetine in oncology is supported by an open study demonstrating
tolerability and good efficacy on depression in patients with breast cancer (46). An interesting area
of application for the noradrenergic reboxetine could be the treatment of fatigue or sexual
disturbances induced by SSRIs, but controlled studies are needed.
Selective Serotonin Reuptake Inhibitors (SSRIs) are a class of compounds (including fluoxetine,
fluovaxamine, paroxetine, sertraline, citalopram and escitalopram) that present a unique mechanism
of action (the selective inhibition of the 5HT reuptake, blocking the 5HT presynaptic transporter)
but with a differentiated clinical profile due to minor pharmacodynamic activities. For example,
paroxetine is the only SSRI with minimal anticholinergic activity, and citalopram shows a modest
antihistaminergic blockade.
SSRIs differ among themselves concerning metabolism and kinetics. Paroxetine and fluoxetine are
potent inhibitors of the isoenzyme 2D6 of cytochrome P450 and can increase the catabolism of
other compounds that are metabolized through the same isoenzyme, for example, tamoxifen.
The half-life of all SSRIs is between 7 and 33 hours, while fluoxetine (with its main metabolite
norfluoxetine) has a half-life of 7-10 days. All compounds can be used once a day, except
fluvoxamine, which must be given twice a day.
In spite of their good global tolerability in oncological patients, the increase of serotonergic tone
due to SSRIs suggests some cautions, particularly in the first one to two weeks of treatment. Nausea
12
is the most frequent side effect of SSRIs, occurring in about 20-25% of patients in the first days of
the treatment and disappearing within a few days. This side effect, although subjective and
temporary, can contribute to a patient's non-adherence, particularly if given at close range with
chemotherapies. SSRI treatments have to start 10-15 days before chemotherapy to avoid the overlap
of such side effects. Moreover, if nausea becomes an operational problem with a risk of drop-out, it
is useful in association with a substituted benzamide (levosulpiride or amisulpride). Amisulpride,
besides attenuating the nausea, induces a faster antidepressant response (48, 49). Less frequent are
constipation (13%) and dry mouth (18%), particularly with paroxetine, hyperhidrosis (10-15%) and
tremor (approximately 10%). Tremor can be an important and early sign for a serotonergic
syndrome when the SSRI is associated with other compounds, for example, tramadol, which exerts
an adjunctive serotonergic activity.
Different side effects are observed among SSRIs: sertraline mainly exerts an increase of guts
peristalsis, and paroxetine mainly induces constipation; in the first phases of treatment, fluoxetine
and escitalopram present a possible activation that requires a transient BDZ, even if, after a few
weeks, all SSRIs demonstrate similar anti-anxiety activity (27). In oncological patients, particularly
in the presence of hematological alterations in platelets, SSRI use must be monitored because of
their anti-aggregation activity, especially if the patients are taking antiplatelet drugs. However, the
bleeding risk during SSRI treatment alone is not increased in comparison with the general
population (50,51).
Patients that have a reduction of dopaminergic functionality, such as exhausted individuals and
those treated with SSRIs, can incur extrapyramidal symptoms, particularly tremor and bradykinesia.
This is because an SSRI-related increase in 5HT can reduce the dopamine levels at basal ganglia
(52). The same mechanism, i.e., the serotonergic inhibition of dopamine, occurs also at the cortico-
frontal level and is responsible for the emotional blunting sometimes observed in patients treated
13
with SSRIs. This effect can be counteracted by drugs with noradrenergic or dopaminergic activity,
such as venlafaxine, duloxetine or bupropion.
The number of clinical trials of SSRIs in oncology is higher than with all other classes of
antidepressants, but it is still inadequate given the clinical relevance of the problem (for a larger
review, see references 6 and 27).
Briefly, from these studies, it appears that paroxetine demonstrates a similar effectiveness to
amitriptyline but a better tolerability (53); paroxetine is more effective than placebo in preventing
depression in patients with melanoma who are being treated with interferon (54); paroxetine results
in a significant reduction of depressive symptoms versus placebo in patients treated with paroxetine
during chemotherapy, but without improvement of fatigue (55); fluoxetine is more effective than
placebo in oncological patients with major depression, but has more side effects (observed in 33%
of patients) (56), particularly on the gastroenteric system (57), while fluoxetine is better tolerated
than TCAs (58).
Another very important and diffuse use of SSRIs in oncology is the treatment of hot flushes induced
by ovariectomy, chemotherapies, or, more frequently, anti-estrogen approaches (such as tamoxifen
and/or aromathase inhibitors)(59,60). For such patients, the use of substitute estrogens is not
possible (because of the oncological risk), but a reduction in the intensity and frequency of hot
flushes was observed with several antidepressants, such as citalopram (61), sertraline (62),
paroxetine (63-65) duloxetine and escitalopram (66). This anti-hot flush activity is probably due to
the intra-cerebral estrogenic increase induced by antidepressants and a consequent reduction of
thermo-dysregulation. Caution must be used with paroxetine in association with tamoxifen because
of the presence of pharmaco-kinetic interactions reducing, in part, the clinical activity of tamoxifen
(see section: "Pharmacologic interactions of antidepressants in oncology").
14
The SNRIs (Serotonin Norepinephrine Reuptake Inhibitors) are the antidepressants venlafaxine,
duloxetine and milnacipram, named “dual” because they act on both norepinephrine and serotonin
reuptake inhibition. Another “dual” is buproprion that inhibits the reuptake of norepinephrine and
dopamine (NDRI). Mirtazapine also demonstrates an activity on NE and 5HT but with a different
mechanism (through an activity on pre-synaptic NE receptors and on selective post-synaptic 5HT
receptors) and is called NASSA (Noradrenergic and Selective Serotonergic Antidepressant).
SNRIs demonstrate the same broad spectrum of TCAs on NE and 5HT, without receptor H1, alfa1
and muscarinic blockade activity, thus showing a tolerability profile similar to SSRIs and safer than
TCAs. Pharmaco-dynamic and kinetic differences exist among SNRIs: venlafaxine at low doses
(75-150 mg) shows a serotonergic more than noradrenergic activity, while it is more active on both
transmitters at higher doses (150-300 mg); duloxetine is more balanced on 5HT and NE at any dose
(67,68); milnacipram is more noradrenergic than serotonergic.
The most common side effects of SNRIs are nausea, headache, restlessness, dry mouth, insomnia or
drowsiness, constipation and dizziness; all these side effects are related to the increase of 5HT
and/or NE tone, they are present in the first weeks of treatment and they then demonstrate an
attenuation or disappearance.
The noradrenergic activity results in higher efficacy on residual and somatic symptoms of
depression, particularly the painful physical symptom cluster (69). NE reuptake inhibition can also
increase the risk of hypertension (70), particularly with high doses of venlafaxine (5% of patients at
150 mg/day and 12% with doses approximately 300 mg/day); this problem is more probable in
patients with unstable hypertension; because of this, during the first period of SNRIs treatment,
pressure monitoring is recommended.
As previously described for SSRIs, SNRIs are also effective and safe in the prevention and
treatment of hot flashes, even at low doses (venlafaxine 75 mg/day; duloxetine 60 mg/day) (14,62).
15
The clinical response, measured as frequency and intensity of attacks, is already present at four
weeks and improves at eight weeks (15,66). Similar data are observed for venlafaxine in terms of
autonomic phenomena observed in patients treated with hormonal therapy in prostate cancer
(71,72).
The low activity of SNRIs on the P450 system, even in the absence of controlled and targeted
studies, allows one to theorize a pharmacokinetic safety of this class as well when used during
oncological therapies (47).
An important aspect concerning antidepressant use in oncology is their neurotrophic activity,
through an antidepressant-induced increase of neuronal growth factors (such as BDNF and NGF).
This potential can be useful in reducing peripheral and central neuronal damages induced by several
chemotherapies (such as vinca alkaloids, platinum compounds and taxans). Some pivotal data
support such a hypothesis (20), both for venlafaxine, which seems to antagonize, in part, the
chemotherapeutic-induced neurotoxicity (73-76), and for duloxetine, which increases BDNF in
depressed oncological patients (35).
In oncological patients, the possibility of successfully treating fatigue with bupropion is very
interesting (76).
The relevant antalgic effectiveness of dual-acting antidepressants will be discussed later (see
“antidepressants and pain”).
The NASSA mirtazapine acts through the presynaptic alpha-adrenergic inhibitor receptor blockade,
thereby increasing the NE and 5HT release. On the post-synaptic 5HT receptors, mirtazapine shows
a selective activity, with a stimulation of 5HT1a receptors (anxiolytic and antidepressant activities)
and a blockade both of 5HT2a receptors (with reduced sexual side effects) and 5HT2c (with
potentiation of sedative side effects). Moreover, the blockade of 5HT3, which differentiates
16
mirtazapine from all other serotonergic agents (which are agonists of 5HT3), is linked to an anti-
nausea effect, and as a result, mirtazapine is useful when depression and nausea are present during
chemotherapeutic treatment (77-79). The relevant anti-histaminergic activity of mirtazapine is
favorable in patients requiring sedation (for anxiety or insomnia) or when a loss of appetite
complicates the general medical situation. Nevertheless, it is appropriate to remember that the
sedative effect of mirtazapine is mainly present at 15 mg because at higher dosages (30-45 mg), the
activating noradrenergic effect (dose-dependent) counteracts the sedative one induced by the
blockade of H1 and 5HT2c (80-83).
As with SSRIs and SNRIs, mirtazapine is also useful in the management of hot flushes (84).
Substituted benzamides act as antipsychotics at high dosage (acting as D2 post-synaptic agents),
while at low doses, they demonstrate good effectiveness on somatic and depressive symptoms,
improving coenesthesis, fatigue and volition through targeted activity on mesolimbic circuits,
particularly on D3 and D4 receptors (49,85).
To this class belong compounds that demonstrate a broad clinical spectrum of action: from anti-
emetic activity (metoclopramide, cisapride and levosulpiride) to gastroprotective activity (sulpiride,
levosulpiride) and from neuroleptic activity (sultopride, tiapride) to antidepressant activity
(amisulpride, levosulpiride).
In particular, amisulpride at low doses (equal to or less than 50 mg/day) acts specifically to
antagonize the presynaptic receptors, thereby increasing dopaminergic release, particularly at the
mesocorticolimbic level. The regulation of mood and coenesthesia of this circuit is also useful in
oncological patients; for this reason, substituted benzamides have recently been put into therapeutic
protocols for quality of life improvement in oncology (49,85).
17
The clinical response to amisulpride is fast, with an improvement of several depressive symptoms,
particularly the cluster related to the somatic component (i.e., asthenia, hyporexia, and avolition);
this improvement is reached within a few days (48) in oncological patients (49).
Levosulpiride is more specific on somatoform symptoms and is dispensed also for parenteral use;
very frequently, this compound is used for nausea, including in patients that demonstrate such a
symptom in the first phases of SSRI treatment (7).
For all benzamides, but particularly for the more potent ones with respect to the dopaminergic
system, such as amisulpride and levosulpiride, several clinical cautions are needed.
First, they cause a fast and relevant increase of prolactin, sometimes with galactorrhoea, oligo- or
amenorrhoea (86), and symptoms of reduced libido and erectile dysfunction. In oncological patients
with breast pathologies, benzamides are contraindicated in the phases in which tumor growth can be
significantly influenced by sexual hormones.
Benzamides can cause an increase in body weight, but this fact can be extremely useful in some
oncological patients, particularly in advanced phases of the disease.
In older patients, strict caution must be used in the temporary use of substituted benzamides, as the
presynaptic selectivity is no longer present (because of age-related dysfunction of the dopaminergic
pathways) and because benzamides can also act at low doses as a neuroleptic, blocking D2
postsynaptic receptors and inducing extrapyramidal symptoms (e.g., tremor, bradykinesia, and
rigidity) (69).
The S-adenosyl-L-methionine (SAMe) is an endogenous compound that is effective on mood and
fatigue (87-92), even if some data are conflicting (93). The SAMe is an important donor of methyl
groups, essential for the biosynthesis of several neurotransmitters (5HT,NE,DA) (94,95). After
intravenous and intramuscular administration, absorption is practically complete, while oral
18
administration demonstrates a very low bioavailability. Parenteral administration shows
effectiveness that is faster than but comparable to TCAs (96).
In psycho-oncology, SAMe is indicated in the short term treatment of depression, with a fast
restoration of well-being through an improvement of asthenia or fatigue (97). At 800-1600 mg/day,
administered in 100 cc of physiological solution for 10-14 days, it is used in psycho-oncology
particularly as an enhancer during the latency of traditional antidepressant therapy or when a fast
clinical response is needed (98).
Side effects are clinically negligible. Rarely, it presents a transient activation that in bipolar patients
treated during a depressed phase can induce a fast switch.
Pharmacological interactions of antidepressants in oncology
Several drugs also used in oncology are metabolized by the cytochrome P450. Particularly with
respect to the 2D6 isoenzyme, fluoxetine and paroxetine exert a strong inhibitory activity, with a
consequent increase of plasma levels of drugs using the same metabolic pathway. The other SSRIs
and SNRIs do not demonstrate a clinically significant interaction with 2D6 (99).
Caution must be used due to the possibility of a serotonergic syndrome as a consequence of additive
effects of serotonergic compounds, for example, secondary to the concomitant use of SSRIs/SNRIs
(particularly venlafaxine) or SSRIs and tramadol (39,40,100,101). The main symptoms are
autonomic dysfunctions (e.g., fever, nausea, vomiting, diarrhea, and hyperhidrosis) and
neuromuscular signs (e.g., myoclonus, hyperreflexia, tremor, and lack of motor coordination)(102).
The clinical relevance of the interaction between paroxetine and tamoxifen is still debated,
specifically, whether there is a real clinical impact of the reduced efficacy of tamoxifen caused by
paroxetine (103,104) rather than a simple pharmakinetic interference without clinical consequences
19
(105). In any case, patients treated with tamoxifen or aromatase inhibitors and that need
antidepressant treatment must be given compounds with minor activity on cytochromes (see above).
Antidepressants and pain treatment
In advanced oncological disease, more than 90% of patients demonstrate pain with different levels
of intensity (106). oncological pain shows a complex pathogenesis that cannot always be controlled
with just an analgesic approach, but rather, it frequently needs analysis and treatment of the
emotional and cognitive components, if present.
Antidepressants (AD) and anticonvulsants (AED) demonstrate a direct antalgic mechanism on pain,
independently from the presence of anxiety and/or depression and are considered as adjuvant
analgesics in each step of the WHO analgesic scale (107). Their activity is actually complete when
the emotional and cognitive components of pain are also controlled (43).
The effective therapy of chronic pain is usually the result of a difficult balance among symptom
control, the side effects of treatment and the resulting quality of life. A correct therapeutic strategy
for pain other than the mainstay physical components of pain (i.e., site, intensity, duration, and
aggravating factors) must include consideration of the suffering based on the patient’s previous
experience, beliefs about pain, personality, relational context and, particularly, on the his or her
emotional state because stress, anxiety and depression reduce the pain threshold (108). Major
depression is present in between 30 and 54% percent of patients with chronic pain (109), and the
presence of painful symptoms is highly predictive of a subsequent major depression (110).
Moreover, depression and pain share, in part, several biologic neurotransmitter-related, hormonal,
immune and neurotrophic substrates.
A norepinephrine and serotonin deficit on the one hand is considered to be a main pathogenetic
cause of depression, whereas on the other hand, the same deficit reduces the efficacy of the inhibitor
descendent system that projects from the periacqueductal griseum (PAG) to the spinal cord. An
20
increase of proinflammatory cytokines is present both in depression and in pain, as is well
supported by the flogistic sickness syndrome in which occurs a similar cluster of symptoms (i.e.,
hypovolition, asthenia, and hyperalgesia) to that observed in depression (43). During chronic stress,
which is very frequent in patients with chronic pain, the hyperactivation of the HPA axis leads to an
increased release of cortisol and consequently of cytokines, both of which are involved in pain and
depression (30).
On the neurotransmitter level, pain is modulated and transmitted through serotonergic,
noradrenergic, GABAergic, glutamatergic and opioid systems, all related to the antidepressant and
anticonvulsant mechanism of action. For example, with dual-acting antidepressants such as
duloxetine, venlafaxine, and milnacipram, the contextual increase of 5HT and NE at mesencephalic
and limbic levels (amygdala and accumbens) induces the release of endogenous opioids, with a
consequent antalgic effect characterized by a pain threshold increase and reduced pain perception
(111).
In neuropathic pain, both antidepressants and anticonvulsants act through the reinforcement of
inhibitory descendent mechanisms and the downregulation of the hyperfunctioning sodium and
calcium channels, modulating the abnormal interactions between the central nervous and autonomic
systems (112). In this way, characteristic phenomena of neuropathic pain (such as hyperalgesia,
allodynia and wind-up) are reduced by ADs and AEDs that represent the first-choice classes for this
pathology (113).
Antidepressants work on pain via a direct mechanism (114), thereby demonstrating analgesic
activity that is independent from their activity on mood. The antalgic response is faster than the
antidepressant effects; a few hours after the first administration, the reuptake inhibition exerted by
the AD increases the neurotransmitter’s intrasynaptic availability, thus acting on pain inhibitor
systems (115,116).
21
TCAs are commonly used and have been in use for a long time. In spite of their effectiveness in
reducing pain, the presence of a large number of side effects (due to their receptor blockade) limits
their use and particularly their dosage, so that the tolerable dosage is almost always inadequate for a
true antidepressant effect. From the 1980s, several antidepressant mechanisms of action on pain
were proposed: the interaction with the opioid system, the antagonism against NMDA glutamate
receptors, and, more recently, the blockade of the calcium and sodium channels and NO and
prostaglandin E2 dose-dependent inhibitions (117).
In spite of a large body of literature concerning the use of TCAs on pain, up to date studies on
neuropathic oncological pain are lacking (118). In the few studies available, TCAs are used with
low doses, utilizing their sedative and intrinsic antalgic activity without the synergic antidepressant
effect that is essential to normalize the pain threshold (43). The tertiary amines (such as
amitriptyline) are more effective than secondary amines (such as nortriptyline and desipramine)
because of their larger receptorial blockade (119).
SSRIs are also effective in several pain syndromes, both experimental and clinical, and although
their main mechanism of action is serotonergic, they are linked to the opioid systems (120,121). In
several studies on neuropathic pain, SSRIs were less effective than TCAs but better tolerated,
particularly in long-term treatments (122).
The dual antidepressants (venlafaxine and duloxetine) are implemented within the guidelines for the
use of ADs in neuropathic pain because of their favorable balance between effectiveness and safety,
as an alternative to less well-tolerated TCAs (113).
In our clinical experience, venlafaxine (75 mg/day) reduces uncontrolled pain and concomitantly
acts on its cognitive and emotional aspects, encouraging a better adjustment of the patient to the
disease (123). Duloxetine is the first antidepressant approved by the Food and Drug Administration
(FDA) for the treatment of neuropathic pain, particularly in diabetic neuropathy and, more recently,
22
for tension-related pain (124,125). Duloxetine also demonstrates a contextual activity on pain and
mood in oncological patients (26).
References
1 Stiefel FC, Kornblith AB, Holland JC. Changes in the prescription patterns of psychotropic drugs
for cancer patients during a 10-year period. Cancer. 1990; 65(4):1048-53.
2 Punekar RS, Short PF, Moran JR. Use of psychotropic medications by US cancer survivors.
Psychooncology 2011; Sep. 9 [Epub ahead of print].
3 Rayner L, Price A, Evans A, Valsraj K, Hotopf M, Higginson IJ. Antidepressants for the
treatment of depression in palliative care: systematic review and meta-analysis. Palliat Med. 2011;
25(1):36-51.
4 Liénard A, Merckaert I, Libert Y, Delvaux N, Marchal S, Boniver J, Etienne AM, Klastersky J,
Reynaert C, Scalliet P, Slachmuylder JL, Razavi D. Factors that influence cancer patients’ anxiety
following a medical consultation: impact of a communication skills training programme for
physicians. Ann Oncol. 2006; 17(9):1450-8.
5 Surget A, Tanti A, Leonardo ED, Laugeray A, Rainer Q, Touma C, Palme R, Griebel G,
Ibarguen-Vargas Y, Hen R, Belzung C. Antidepressants recruit new neurons to improve stress
response regulation. Mol Psychiatry. 2011; 16(12):1177-88.
6 Williams S, Dale J. The effectiveness of treatment for depression/depressive symptoms in adults
with cancer: a systematic review. Br J Cancer. 2006; 94(3):372-90.
7 Grassi L, Nanni MG, Uchitomi Y, Riba M, Kissane DW, Maj M, Sartorius N. Pharmaco-theray of
depression in people with cancer; in Kissane DW, Maj M, Sartorius N (Eds): Depression and
Cancer. Chichester, Wiley, 2010.
23
8 Okamura M, Akizuki N, Nakano T, Shimizu K, Ito T, Akechi T, Uchitomi Y. Clinical experience
of the use of a pharmacological treatment algorithm for major depressive disorder in patients with
advanced cancer. Psychooncology. 2008; 17(2):154-60.
9 Gilliam FG, Santos JM. Adverse psychiatric effects of antiepileptic drugs. Epilepsy Res. 2006;
68(1):67-9.
10 Capuron L, Ravaud A, Miller AH, Dantzer R. Baseline mood and psychosocial characteristics of
patients developing depressive symptoms during interleukin- 2 and/or interferon-alpha cancer
therapy. Brain Behav Immun. 2004; 18(3):205-13.
11 Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB, ,Miller
AH. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine
responsiveness of symptom dimensions. Neuropsychopharmacology. 2002; 26(5):643-52.
12 Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpé S, Maes M. IDO and interferon-alpha-
induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol
Psychiatry. 2005; 10(6):538-44.
13 Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, Greiner K,
Nemeroff CB, Miller AH. Paroxetine for the prevention of depression induced by high-dose
interferon alfa. N Engl J Med. 2001; 344(13):961- 6.
14 Loprinzi CL, Levitt R, Barton D, Sloan JA, Dakhil SR, Nikcevich DA, Bearden JD 3rd
, Mailliard
JA, Tschetter LK, Ficht TR, Klugler JW. Phase III comparison of depomedroxyprogesterone acetate
to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. J
Clin Oncol .2006; 24(9):1409-14.
24
15 Biglia N, Torta R, Roagna R, Maggiorotto F, Cacciari F, Ponzone R, Kubatzki F, Sismondi P.
Evaluation of low-dose venlafaxine hydrochloride for the therapy of hot flushes in breast cancer
survivors. Maturitas. 2005; 52(1):78-85.
16 Massie MJ, Holland JC. Depression and the hospitalized cancer patient. J Clin Psychiatry. 1990;
51(7):12-9.
17 Potash M, Breitbart W. Affective disorders in advanced cancer. Hematol Oncol Clin North Am.
2002; 16(3):671-700.
18 Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes.
Nature Reviews Cancer. 2007; 7(3):192-201.
19 Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K, Whedon MB, Bivens S,
Mitchell T, Greenberg ER, Silberfarb PM. Neuropsychologic impact of standard- dose systemic
chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002;
20(2):485-93.
20 Caldera P, Berra C, Amodeo L, Malabaila A, Torta R, Mussa A. Evaluation of emotional and
cognitive neurotoxicity in course of chemotherapy for cancer: preliminary data from a multicentric
study. Proceedings of the 8th World Congress of Psycho-Oncology, Venice, Psycho-oncology,
2006:S191.
21 Chaturvedi SK, Maguire P, Hopwood P. Antidepressant medications in cancer patients. Psycho-
Oncology. 1994; 3:57-60.
22 Passik SD, Breitbart WS. Depression in patients with pancreatic carcinoma: diagnostic and
treatment issues. Cancer. 1996; 78(3):615-26.
25
23 Sheibani-Rad S, Velanovich V. Effects of depression on the survival of pancreatic
adenocarcinoma. Pancreas 2006; 32(1):58-61.
24 Tian J, Chen ZC, Hang LF. The effects of psychological status of the patients with digestive
system cancers on prognosis of the disease. Cancer Nurs. 2009; 32(3):230-5.
25 Castelli L, Binaschi L, Caldera P, Mussa A, Torta R. Fast screening of depression in cancer
patients: the effectiveness of the HADS. Eur J Cancer Care. 2010; 20(4):528-33.
26 Torta R, Leombruni P, Borio R, Castelli L. Duloxetine for the treatment of mood disorder in
cancer patients: a 12-week case-control clinical trial. Human Psychopharmacol. 2011; Jul 12 [epub
ahead of print].
27 Miguel C, Albuquerque E. Drug Interaction in Psycho-Oncology: Antidepressants and
Antineoplastics. Pharmacolgy 2011; 88(5-6):333-9.
28 Park HY, Lee BJ, Kim JH, Bae JN, Hahm BJ. Rapid improvement of depression and quality of
life with escitalopram treatment in outpatients with breast cancer: A 12-week, open-label
prospective trial. Prog Neuropsychopharmacol Biol Psychiatry. 2011; Nov 28 [Epub ahead of
print].
29 Hem E, Loge JH, Haldorsen T, Ekeberg Ø. Suicide risk in cancer patients from 1960 to 1999. J
Clin Oncol .2004; 22(20):4209-16.
30 Wardenaar KJ, Vreeburg SA, van Veen T, Giltay EJ, Veen G, Penninx BW, Zitman FG.
Dimensions of depression and anxiety and the hypothalamo-pituitary-adrenal axis. Biol Psychiatry.
2011; 69(4):366-73.
31 Anacker C, Zunszain PA, Carvgalho LA, Pariante CM. The glucocorticoid receptor: pivot of
depression and of antidepressant treatment? Psychoneuroendocrionology. 2010; 36(3):415-25.
26
32 Russo-Neustadt AA, Chen MJ. Brain-derived neurotrophic factor and antidepressant activity.
Curr Pharm Des. 2005; 11(12):1495-1510.
33 Hashimoto K. Brain-derived neurotrophic factor as a biomarker for mood disorders: anhistorical
overview and future directions. Psychiatry Clin Neurosci. 2010; 64(4):341-57.
34 Molendijk ML, Bus BA, Spinhoven P, Penninx BW, Kenis G, Prickaerts J, Voshaar RC, Ezinga
BM. Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait
issues, clinical features and pharmacological treatment. Mol Psychiatry. 2011; Nov 16 [Epub ahead
of print].
35 Torta R, Amodeo L, Tascedda F, Brunello N. Antidepressants and neurotrophic factors in
depressed oncological al patients. 2011 (submitted).
36 Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT. Increased hippocampal BDNF
immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry. 2001;
50(4):260-5.
37 Kayl AE, Wefel JS, Meyers CA. Chemotherapy and cognition: effects, potential mechanisms,
and management. Am J Ther. 2006; 13(4):362-9.
38 Miura H,Ozak N, Sawada M, Isobe K, Ohta T, Nagatsu T. A link between stress and depression:
shifts in the balance between the kynurenine and serotonin pathways of tryptophan metabolism and
the etiology and pathophysiology of depression. Stress. 2008; 11:(3):198-209.
39 Markowitz JS, Patrick KS. Venlafaxine-tramadol similarities. Med Hypotheses. 1998;
51(2):167-8.
40 Houlihan DJ. Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and
mirtazapine. Ann Pharmacother. 2004; 38(3):411-3.
27
41 Hong RA, Iimura T, Sumida KN, Eager RM. Cardio-oncology/onco-cardiology. Clin Cardiol.
2010; 33:(12):733-7.
42 Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer TreatRev.
2011; 37(4):300-11.
43 Torta R, Munari J. Symptom cluster: depression and pain. Surg Oncol. 2010; 19(3):155-9.
44 Razavi D, Kormoss N, Collard A, Farvacques C, Delvaux N. Comparative study of the efficacy
and safety of trazodone versus clorazepate in the treatment of adjustment disorders in cancer
patients: a pilot study. J Int Med Res. 1999; 27(6):264-72.
45 Davis MP. Does trazodone have a role in palliating symptoms? Support Care Cancer. 2007;
15(2):221-4.
46 Grassi L, Biancosino B, Marmai L, Righi R. Effect of reboxetine on major depressive disorder in
breast cancer patients: an open-label study. J Clin Psychiatry. 2004; 65(4):515-20.
47 Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Araba A, Blanchard
R, Nguyen A, Ullmer L, Haydem J, Lemler S, Weinshilboum RM, Rae JM, Hayse DF, Flockhart
DA. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast
cancer treatment. J Natl Cancer Inst. 2005; 97(1):30-9.
48 Amore M, Jori MC; AMISERT Investigators. Faster response on amisulpride 50 mg versus
sertraline 50-100 mg in patients with dysthymia or double depression: a randomized, double-blind,
parallel group study. Int Clin Psychopharmacol. 2001; 16(6):317-24.
49 Torta R, Berra C, Binaschi L, Borio R. Amisulpride in the short-term treatment of depressive
and physical symptoms in cancer patients during chemotherapies. Support Care Cancer. 2007;
15(5):539-46.
28
50 Bak S, Tsiropoulous I, Kjaersgaard JO, Andersen M, Mellerup E, Hallas J, Garcìa-Rodrìguez
LA, Christensen K, Gaist D. Selective serotonin reuptake inhibitors and the risk of stroke: a
population based case-control study. Stroke 2002; 33(6):1465-73.
51 Kurdyak PA, Juurlink DN, Kopp A, Herrmann N, Mamdani MM. Antidepressants, warfarin, and
the risk of hemorrhage. J Clin Psychopharmacol 2005; 25(6):561-4.
52 Barone P. Treatment of depressive symptoms in Parkinson's disease. Eur J Neurol. 2011; 18
Suppl 1:11-5.
53 Pezzella G, Moslinger-Gehmayr R, Contu A. Treatment of depression in patients with breast
cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Res Treat. 2001;
70(1):1-10.
54 Torta R, Siri I, Caldera P. Sertraline effectiveness and safety in depressed oncological patients.
Support Care Cancer 2008; 16(1):83-91.
55 Roscoe JA, Morrow GR, Hickok JT, Mustian KM, Griggs JJ, Matteson SE, Bushunow P, Qazi
R, Smith B. Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer
patients receiving chemotherapy. Breast Cancer Res Treat. 2005; 89(3):243-9.
56 Razavi D, Allilaire JF, Smith M, Salimpour A, Verra M, Desclaux B, Saltel P, Piollet I,
Guavain-Piguard A, Trichard C, Cordier B, Fresco R, Guillibert E, Sechter D, Orth JP, Bouhassira
M, Mesters P, Blin P. The effect of fluoxetine on anxiety and depression symptoms in cancer
patients. Acta Psychiatr Scand. 1996; 94(3): 205-10.
57 Fisch MJ, Loehrer PJ, Kristeller J, Passik S, Jung SH, Shen J, Arquette MA, Brames MJ,
Einhorn LH; Hoosier Oncology Group. Fluoxetine versus placebo in advanced cancer outpatients: a
double-blinded trial of the Hoosier Oncology Group. J Clin Oncol. 2003; 21(10):1937-43.
29
58 Cheer SM, Goa KL. Fluoxetine: a review of its therapeutic potential in the treatment of
depression associated with physical illness. Drugs. 2001; 61(1):81-110.
59 Mom CH, Bujis C, Willemse PH, Mourits MJ, de Vries EG. Hot flushes in breast cancer
patients. Crit Rev Oncol Haematol. 2006; 57(1):63-77.
60 Gupta P, Sturdee DW, Palin SL, Majumder K, Fear R, Marshall T, Paterson I. Menopausal
symptoms in women treated for breast cancer: the prevalence and severity of symptoms and their
perceived effects on quality of life. Climacteric. 2006; 9(1):49-58.
61 Barton DL, Loprinzi CL, Novotny P, Shanafelt T, Sloan J, Wahner-Roedler D, Rummans TA,
Christensen B, Dakhill SR, Martin LS. Pilot evaluation of citalopram for the relief of hot flashes. J
Support Oncol. 2003; 1(1):47-51.
62 Kimmick GG, Lovato J, McQuellon R, Robinson E, Muss HB. Randomized, double-blind,
placebo controlled, crossover study of sertraline (Zoloft) for the treatment of hot flushes in women
with early stage breast cancer taking tamoxifen. Breast J. 2006; 12(2):114-22.
63 Stearns V. Serotonergic agents as an alternative to hormonal therapy for the treatment of
menopausal vasomotor symptoms. Treat Endocrinol. 2006; 5(3):83-7.
64 Loprinzi CL, Kugler JW, Sloan JA, Mailliard J, LaVasseur BI, Barton DL, Novotny PJ, Dakhil
SR, Rodger K, Rummans TA, Christensen BJ. Venlafaxine in management of hot flashes in
survivors of breast cancer: a randomized controlled trial. Lancet 2000; 356(9247):2059-63.
65 Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z,
Flockhart DA. Active tamoxifen metabolite plasma concentrations after coadministration of
tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003;
95(23):1758-64.
30
66 Carroll DG, Kelley KW. Use of antidepressants for management of hot flashes.
Pharmacotherapy. 2009; 29(11):1357-74.
67 Wong DT, Bymaster FP, Mayle DA, Reid LR, Krushinski JH, Robertson DW. LY248686, a new
inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology. 1993; 8(1):23-33.
68 Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL,
Hemrick-.Luecke SK, Wong DT. Comparative affinity of duloxetine and venlafaxine for serotonin
and norepinephrine transporters in vivo and in vivo, human serotonin receptors subtypes, and other
neuronal receptors. Neuropsychopharmacology. 2001; 25(6):871-80.
69 Fava M, Detke MJ, Balestrieri M, Wang F, Raskin J, Perachia D. Management of depression
relapse: reinitiation of duloxetine treatment or dose increase. J Psychiatr Res. 2006; 40(4):328-36.
70 Schatzberg A, Roose S. A double-blind, placebo-controlled study of venlafaxine and fluoxetine
in geriatric outpatients with major depression. Am J Geriatr Psychiatry. 2006; 14(4):361-70.
71 Quella SK, Loprinzi CL, Sloan J, Novotny P, Perez EA, Burch PA, Antolack SJ Jr, Pisanski TM.
Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation
therapy for prostate cancer. J Urol. 1999; 162(1):98-102.
72 Adelson KB, Loprinzi CL, Hershman DL. Treatment of hot flushes in breast and prostate cancer.
Expert Opin Pharmacother. 2005; 6(7):1095-6.
73 Durand JP, Brezault C, Goldwasser F. Protection against oxaliplatin acute neurosensory toxicity
by venlafaxine. Anticancer Drugs. 2003; 14:(6):423-5.
74 Durand JP, Alexandre J, Guillevin L, Goldwasser F. Clinical activity of venlafaxine and
topiramate against oxaliplatin-induced disabling permanent neuropathy. Anticancer Drugs. 2005;
16(5): 587-91.
31
75 Grothey A. Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer.
2005; 5 (Suppl 1):S38-46.
76 Carroll JK, Kohli S, Mustian KM, Roscoe JA, Morrow GR. Pharmacologic treatment of cancer-
related fatigue. Oncologist. 2007; (Suppl 1): 43-51.
77 Thompson DS. Mirtazapine for the treatment of depression and nausea in breast and
gynecological oncology. Psychosomatics. 2000; 41(4):356-9.
78 Kast RE. Mirtazapine may be useful in treating nausea and insomnia of cancer chemotherapy.
Support Care Cancer. 2001; 9(6):469-70.
79 Eisensamer B, Rammes G, Gimpl G, Shapa M, Ferrari U, Hapfelmeier G, Bondy B, Parsons C,
Gilling K, Zieglgänsberger W, Holsboer F, Rupprecht R. Antidepressants are functional antagonists
at the serotonin type 3 (5-HT3) receptor. Mol Psychiatry. 2003; 8(12):994-1007.
80 Davis MP, Khawam E, Pozuelo L, Lagman R. Management of symptoms associated with
advanced cancer: olanzapine and mirtazapine. A World Health Organization project. Expert Rev
Anticancer Ther. 2002; 2(4):365-76.
81 Cardona D. Pharmacological therapy of cancer anorexia-cachexia. Nutr Hosp. 2006; 21(Suppl
3):17-26.
82 Pasquini M, Biondi M, Costantini A, Cairoli F, Ferrarese G, Picardi A, .Sternberg C. Detection
and treatment of depressive and anxiety disorders among cancer patients: feasibility and preliminary
findings from a liaison service in an oncology division. Depress Anxiety. 2006; 23(7):441-8.
83 Riechelmann RP, Burman D, Tannock IF, Rodin G, Zimmermann C. Phase II trial of
mirtazapine for cancer-related cachexia and anorexia. Am J Hosp Palliat Care. 2010; 27(2):106-10.
32
84 Perez DG, Loprinzi CL, Barton DL, Pockaj BA, Sloan J, Novotny PJ, Christensen BJ. Pilot
evaluation of mirtazapine for the treatment of hot flashes. J Support Oncol. 2004; 2(1):50-6.
85 De Lima MS, Hotopf M. Benefits and risks of pharmacotherapy for dysthymia: a systematic
appraisal of the evidence. Drug Saf. 2003; 26(1):55-64.
86 Paparrigopoulos T, Liappas J, Tzavellas E, Mourikis I, Soldatos C. Amisulpride-induced
hyperprolactinemia is reversible following discontinuation. Prog Neuropsychopharmacol Biol
Psychiatry. 2007; 31(1):92-6.
87 Volkmann H, Norregaard J, Jacobsen S, Danneskiold-Samsøe B, Knoke G, Nehrdich D. Double-
blind, placebo-controlled cross-over study of intravenous S-adenosyl-L-methionine in patients with
fibromyalgia. Scand J Rheumatol. 1997; 26(3):206-11.
88 Torta R, Cicolin A, Keller R. Transmethylation and affective disorders. Arch Gerontol Geriatr
1998; (Suppl 6):499-506.
89 Pancheri P, Scapicchio P, Delle Chiaie R. A double-blind, randomized parallel-group, efficacy
and safety study of intramuscular S-adenosyl-L-methionine 1,4- butanedisulphonate (SAMe) versus
imipramine in patients with major depressive disorder. Int J Neuropsychopharmacol. 2002;
5(4):287-94.
90 Delle Chiaie R, Pancheri P, Scapicchio P. Efficacy and tolerability of oral and intramuscular S-
adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression:
comparison with imipramine in 2 multicenter studies. Am J Clin Nutr. 2002; 76(5):1172-6.
91 Papakostas GI, Alpert JE, Fava M. S-adenosyl-methionine in depression: a comprehensive
review of the literature. Curr Psychiatry Rep. 2003; 5(6):460-6.
33
92 Alpert JE, Papakostas G, Mischoulon D, Worthington JJ 3rd
, Petersen T, Mahal Y, Burns A,
Bottiglieri T, Nierenberg AA, Fava M. S-adenosyl-L-methionine (SAMe) as an adjunct for resistant
major depressive disorder: an open trial following partial or nonresponse to selective serotonin
reuptake inhibitors or venlafaxine. J Clin Psychopharmacol. 2004; 24(6):661-4.
93 Thachil AF, Mohan R, Bhugra D. The evidence base of complementary and alternative therapies
in depression. J Affect Disord. 2007; 97(1-3):23-35.
94 Baldessarini RJ. Neuropharmacology of S-adenosyl-L-methionine. Am J Med. 1987; 83(5A):95-
103.
95 Spillmann M, Fava M. S-adenosyl-methionine (ademethionine) in psychiatric disorders. CNS
Drugs. 1996; 6:416-25.
96 Fava M, Giannelli A, Rapisarda V, et al. Rapidity of onset of the antidepressant effect of
parenteral S-adenosyl-L-methionine. Psychiatry Res. 1995; 56:(3)295-7.
97 Scalabrino A, Airoldi M, Stanizzo MR, Torta R. Transmethylants in oncology: antidepressant
effectiveness. Ann Oncology. 2008; Suppl 19:17.
98 Berra C, Amodeo L, Caldera P, Torta R. New Antidepressants in oncological clinical practice:
data from a single-blind itt comparative study on 558 patients. Psycho-Oncology. 2006; Ssppl
15:28.
99. Owen JR, Nemeroff CB. New antidepressants and the cytochrome P450 system: focus on
venlafaxine, nefazodone, and mirtazapine. Depress Anxiety. 1998; 7 (Suppl 1):24-32.
100 Sauget D, Franco PS, Amaniou M, Mazere J, Dantoine T. Possible serotonergic syndrome
caused by combination of tramadol and sertraline in an elderly woman. Therapie. 2002; 57(3):309-
10.
34
101 Mittino D, Mula M, Monaco F. Serotonin syndrome associated with tramadol sertraline
coadministration. Clin Neuropharmacol. 2004; 27(3):150-1.
102 Lejoyeux M, Rouillon F, Adés J. Prospective evaluation of the serotonin syndrome in
depressed inpatients treated with clomipramine. Acta Psychiatr Scand. 1993; 88(5):369-71.
103 Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, Austin PC, Paszat LF.
Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a
population based cohort study. BMJ. 2010; 8:340.
104 Andersohn F, Willich SN. Interaction of serotonin reuptake inhibitors with tamoxifen. BMJ.
2010; 8:340.
105 Desmarais JE, Looper KJ. Managing menopausal symptoms and depression in tamoxifen users:
implications of drug and medicinal interactions. Maturitas. 2010; 67(4):296-308.
106 Kajer F. The therapy of cancer pain and its integration into a comprehensive supportive care
strategy. Ann Oncology 1997; (Suppl. 3): S15-19.
107 World Health Organization (WHO). Traitement de la douleur cancéreuse. Geneva, Switzerland.
WHO. 1987.
108 Bovero A, Ferrero A, Torta R. A new approach on oncological pain in depressed patients: data
from a clinical study using Brief Adlerian Psychodinamic Psychotherapy. Psycho-Oncology. 2006;
15:S182-83.
109 Banks SM, Kerns RD. Explaining high rates of depression in chronic pain: a diathesisstress
framework. Psychol Bull 1996; 119(1):95-110.
35
110 Torta R. Cancer pain: psycho-oncological aspects and interventions. Proceedings of 20th
World
Congress on Psychosomatic Medicine, Turin 2009.
111 Gray AM, Spencer PSJ, Sewell RDE. The involvement of the opioid system in the
antinociceptive mechanism of action of antidepressant compound. Br J Pharmacol. 1998;
124(4):669-74.
112 Gilron I, Watson CP, Cahill CM, Moulin DE. Neuropathic pain: a practical guide for the
clinician. CMAJ. 2006; 175(3):265-75.
113 Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, Nurmikko T; European
Federation of Neurological Societies. EFNS guidelines on the pharmacological treatment of
neuropathic pain: 2010 revision. Eur J Neurol. 2010; 17(9):1113-88.
114 Egbunike IG, Chaffee BJ. Antidepressants in the management of chronic pain syndromes.
Pharmacotherapy. 1990; 10(4):262-70.
115 Masand PS, Narasimhan M, Patkar AA. Paroxetine for somatic pain associated with physical
illness: a review. Prim Care Companion J Clin Psychiatry. 2006; 8(3):122-30.
116 Micò JA, Ardid D, Berrocoso E, Eschalier A. Antidepressants and pain. Trends Pharmacol Sci.
2006; 27(7):348-54.
117 Yaron I, Shirazi I, Judovich R, Levartovsky D. Caspi D, Yaron M. Fluoxetine and amitriptyline
inhibit nitric oxide, prostaglandin E2, and hyaluronic acid production in human synovial cells and
synovial tissue cultures. Arthritis Rheum. 1999; 42(12):2561-8.
118 McDonald AA, Portenoy RK. How to use antidepressants and anticonvulsants as adjuvant
analgesics in the treatment of neuropatic cancer pain. J Supp Oncology. 2006; 4(1):43-52.
36
119 Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS. Venlafaxine versus imipramine in
painful polyneuropathy: a randomized controlled trial. Neurology. 2003; 60(8):1284-9.
120 Nayebi AR, Hassanpour M, Rezazadeh H. Effect of chronic and acute administration of
fluoxetine and its additive effect with morphine on the behavioural response in the formalin test in
rats. J Pharm Pharmacol. 2001; 53(2):219-25.
121 Singh VP, Jain NK, Kulkarni SK. On the antinociceptive effect of fluoxetine, a selective
serotonin reuptake inhibitor. Brain Res. 2001; 915(2):218-26.
122 Sindrup SH, Otto M, Finnerup NB, Jensen TS. Antidepressants in the treatment of neuropatich
pain. Basic Clin Pharmacol Toxicol. 2005; 96(6):399-400.
123 Bovero A, Torta R. Venlafaxine effectiveness and safety in oncological depressed patients,
2011 (submitted).
124 Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with
painful diabetic neuropathy. Pain. 2005; 116(1-2):109-18.
125 Raskin J, Wang F, Pritchett YL, Goldstein DJ. Duloxetine for patients with diabetic peripheral
neuropathic pain: a 6-month open-label safety study. Pain Med. 2006; 7(5):373-85.